EBANGA

PeakmAb

ansuvimab

Ridgeback Biotherapeutics
BLAIV (INFUSION)POWDERPriority Review
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
30/100

Mechanism of Action

Zaire Ebolavirus Glycoprotein-directed Antibody Interactions

Pharmacologic Class:

Zaire Ebolavirus Glycoprotein-directed Antibody

Indications (2)

infection caused by Orthoebolavirus zairense in adultincluding neonates born to a mother
Company
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics
FL - Miami
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers